Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline
results from three Phase III trials evaluating the efficacy, safety and
tolerability of vilazodone in adult patients with generalized anxiety
disorder (GAD). In two flexible-dose and one fixed-dose GAD trials,
patients who received vilazodone demonstrated statistically significant
improvement from baseline in the Hamilton Rating Scale for Anxiety
(HAM-A) total score versus placebo at week 8, the primary endpoint.
for Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD) investment picks